Can a hemodialysis patient with a history of mild cerebrovascular infarct who is on apixaban be started on erythropoietin three times weekly?

EPO Can Be Initiated in HD Patients with Prior Stroke on Apixaban

Yes, you can initiate EPO 3x/weekly in a hemodialysis patient with a history of mild cerebrovascular infarct who is on apixaban, but this requires careful risk-benefit assessment and close monitoring given the increased thrombotic risk associated with ESAs.

Key Considerations for EPO Initiation

Thrombotic Risk Assessment

The primary concern is that erythropoiesis-stimulating agents (ESAs) including EPO increase thrombotic risk, and prior stroke is an established risk factor for recurrent thromboembolism 1. The guidelines explicitly state that "previous history of thromboses" is a general risk factor that requires careful weighing when prescribing ESAs 1.

However, importantly, there are no data showing that concomitant anticoagulation (like apixaban) modulates this thrombotic risk 1. This means we cannot assume the apixaban provides adequate protection against ESA-related thrombosis.

Dosing and Administration

For hemodialysis patients, the FDA-approved dosing is 2:

• Starting dose: 50-100 Units/kg 3 times weekly
• Route: Intravenous is recommended for hemodialysis patients (though subcutaneous is more efficient, requiring 30% less dose) 3
• Target hemoglobin: <10 g/dL to initiate; reduce/interrupt if approaches or exceeds 11 g/dL 2

The three-times-weekly dosing you propose is standard and appropriate 3, 2.

Monitoring Requirements

Close hemoglobin monitoring is essential 2:

• Monitor hemoglobin at least weekly until stable, then monthly
• Avoid rapid hemoglobin rises (>1 g/dL in 2 weeks) - reduce dose by 25% if this occurs
• Do not target hemoglobin >11 g/dL (increased mortality and cardiovascular events at higher targets) 2

Anticoagulation Considerations

Regarding the apixaban specifically in this HD patient 4, 5, 6:

• Apixaban is used in ESRD/HD patients despite lack of RCT data in this population
• The FDA label states dosing recommendations exist but notes "it is not known whether these concentrations will lead to similar stroke reduction and bleed risk" as in non-ESRD patients 4
• Recent observational data suggests apixaban may reduce stroke risk compared to no anticoagulation in HD patients, though bleeding risk increases 5
• Standard dose (5 mg BID) appears more effective than reduced dose (2.5 mg BID) for stroke prevention in HD patients 6

Clinical Decision Algorithm

Proceed with EPO if:

1. Hemoglobin is <10 g/dL
2. Iron stores are adequate (check and replete first) 2
3. Patient understands increased thrombotic risk given stroke history
4. You can ensure close hemoglobin monitoring (weekly initially)
5. Apixaban dosing is appropriate for the patient's characteristics

Exercise heightened caution if:

• The prior stroke was recent (<3-6 months)
• Patient has other thrombotic risk factors (immobility, malignancy, hypercoagulable state)
• Hemoglobin target cannot be kept conservative (<11 g/dL)

Consider alternatives if:

• Transfusion-dependent anemia can be managed with intermittent transfusions
• The stroke was severe or recent with high recurrence risk
• Patient has had recurrent thrombotic events despite anticoagulation

Common Pitfalls to Avoid

1. Do not target "normal" hemoglobin levels - trials show increased mortality and stroke with targets >11 g/dL 2
2. Do not assume apixaban eliminates ESA thrombotic risk - no evidence supports this 1
3. Do not use IV route without considering SC - SC dosing is 30% more efficient in HD patients, though IV is more convenient 3
4. Do not continue EPO if no response after 12 weeks - evaluate for other causes of anemia 2

The decision ultimately favors cautious initiation with conservative hemoglobin targets and intensive monitoring, as the quality-of-life benefits of correcting anemia in HD patients generally outweigh risks when managed appropriately, even in patients with prior stroke on anticoagulation.